RIGEL PHARMACEUTICALS INC - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by RIGEL PHARMACEUTICALS INC (RIGL) on June 27, 2024. The report details a material corporate action regarding the company's capital structure.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the execution of a reverse stock split.
Material Changes
- Reverse Stock Split: The Company effected a one-for-10 reverse stock split of its common stock, effective 12:01 a.m. Eastern Time on June 27, 2024.
- Shareholder Approval: The split ratio was authorized by stockholders at the annual meeting on May 24, 2024, and finalized by the Board of Directors on June 15, 2024.
- Trading Adjustments: Common stock began trading on a split-adjusted basis on June 27, 2024, under a new CUSIP number (766559702).
- Fractional Shares: No fractional shares were issued. Stockholders entitled to fractional shares received cash payments based on the closing price on the last trading day prior to the effective date.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It does not disclose new risks or contingencies beyond the standard execution of the stock split. The primary purpose is to notify the market of the amendment to the Certificate of Incorporation.
Investor Verification Checklist
- Verify the new CUSIP number (766559702) for trading purposes.
- Confirm the adjusted share count and price per share on brokerage statements.
- Review the Certificate of Amendment (Exhibit 3.1) for full legal details of the capital structure change.
- Check for any cash payments received for fractional shares if applicable.